目的:探讨核糖体S6激酶4(RSK4)蛋白在非小细胞肺癌(NSCLC)组织及癌旁组织中的表达。并阐明其与NSCLC临床病理特征的相关性。
方法:我们分析了2020年6月至2022年6月在浙江大学医学院附属第二医院接受治疗的100例NSCLC患者。患者人口统计学和临床数据,包括性别,年龄,糖尿病史,肿瘤位置,肿瘤分化程度,淋巴结转移,和临床分期,被收集。通过免疫组织化学染色评估组织样品中的RSK4蛋白表达。
结果:RSK4蛋白在35.00%的癌组织中阳性表达,69.00%显著低于癌旁非肿瘤组织(P<0.05)。肿瘤分化程度较低的患者,晚期肿瘤淋巴结转移(TNM)分期,和淋巴结转移显示RSK4表达显著降低,与高分化者相比,早期TNM阶段,无淋巴结转移(均P<0.05)。Cox回归分析表明,TNM阶段,低分化,淋巴结转移对RSK4表达有显著影响(均P<0.05)。生存分析显示,在RSK4表达阳性的患者中,阳性预后生存率更高,为74.29%(26/35)。阴性表达者为53.85%(35/65)(P<0.05)。Spearman相关分析显示RSK4表达与TNM分期呈显著正相关,淋巴结转移,和患者预后(均P<0.05)。
结论:NSCLC组织中RSK4阳性表达与晚期癌症分期显著相关。分化差,淋巴结转移,提示RSK4在非小细胞肺癌中的潜在抑癌作用。这种关联强调了其在NSCLC患者中的预后相关性。
OBJECTIVE: To evaluate the
expression of Ribosomal S6 kinase 4 (RSK4) protein in non-small cell lung cancer (NSCLC) tissues and adjacent non-tumor tissues, and to elucidate its correlation with clinicopathological features of NSCLC.
METHODS: We analyzed 100 NSCLC patients treated at the Second Affiliated Hospital of Zhejiang University School of Medicine from June 2020 to June 2022. Patient demographics and clinical data, including gender, age, history of diabetes, tumor location, degree of tumor differentiation, lymph node metastasis, and clinical stage, were collected. RSK4 protein
expression was assessed in tissue samples via immunohistochemical staining.
RESULTS: RSK4 protein was positively expressed in 35.00% of cancerous tissues, significantly lower than the 69.00% observed in adjacent non-tumor tissues (P < 0.05). Patients with lower tumor differentiation, advanced Tumor Node Metastasis (TNM) stages, and lymph node metastases showed significantly reduced RSK4 expression compared to those with higher differentiation, earlier TNM stages, and no lymph node metastases (all P < 0.05). Cox regression analysis indicated that TNM stage, low differentiation, and lymph node metastases significantly influenced RSK4 expression (all P < 0.05). Survival analysis revealed a higher positive prognosis survival rate of 74.29% (26/35) among patients with positive RSK4 expression, versus 53.85% (35/65) in those with negative
expression (P < 0.05). Spearman correlation analysis demonstrated a significant positive correlation of RSK4
expression with TNM stage, lymph node metastasis, and patient prognosis (all P < 0.05).
CONCLUSIONS: Positive RSK4
expression in NSCLC tissues is significantly correlated with advanced cancer stage, poor differentiation, and presence of lymph node metastasis, suggesting a potential tumor suppressor role for RSK4 in NSCLC. This association underscores its prognostic relevance in NSCLC patients.